Claims
- 1. A method of monitoring a brain wave response of a fetus in utero, comprising the steps of:
(a) removably connecting an auditory transducer to an abdomen of a mother of the fetus; (b) removably connecting at least one biosensor electrode to the mother's abdomen to detect brain wave activity in the fetus; (c) pulsing the transducer with one of rectangular waves and tone pips of a selected frequency to emit pulsed audible sounds at predetermined times; (d) detecting, for each pulsed audible sound, a series of voltage oscillations corresponding to brain stem auditory evoked responses (BAER) of the fetus which are time-locked to the corresponding audible sound; and (e) converting the BAER analog output to BAER digital data.
- 2. The method of monitoring as in claim 1, further comprising the steps of improving a signal to noise ratio of the BAER digital data using a computer-based QEEG (Quantitative EEG) system and passing the BAER digital data through a digital comb filter having a plurality of band pass frequency ranges within an overall frequency range of approximately 50-2000 Hz.
- 3. The method of monitoring as in claim 2, further comprising the steps of collecting a set of stimulus light averages of stimulus data during a stimulation period in which auditory stimuli are presented to the fetus and a set of noise light averages of noise data during a non-stimulation period in which no auditory stimuli are presented to the fetus, where each of the stimulus and noise light averages of data are generated over a plurality of trials.
- 4. The method according to claim 3, wherein each of the light averages comprises a plurality of EEG segments at least between 0.5 and 10 milliseconds in length sampled at least every 50 microseconds.
- 5. The method according to claim 4, wherein each of the trials comprises a plurality of EEG segments approximately 10 milliseconds in length.
- 6. The method according to claim 3, further comprising the steps of:
constructing both the stimulus and noise light averages of data in the time domain; and subjecting the light averages to analysis of frequency composition.
- 7. The method according to claim 6, wherein the light averages are subjected to one of spectral and wavelet analysis using one of a fast fourier transform (FFT) and a wavelet transform.
- 8. The method according to claim 7, wherein the FFT is a multipoint FFT and wherein an initial set of points span an analysis epoch of the BAER and the remaining points are set to a mean value of the initial points.
- 9. The method according to claim 8, wherein the FFT is a 512 point FFT and wherein the initial set comprises approximately 200 points spanning an approximately 10 millisecond analysis epoch of the BAER.
- 10. The method according to claim 7, further comprising the steps of:
determining an amplitude and phase for one of spectral and wavelet components for each of the trials; computing mean amplitude and phase variances for each of the one of spectral and wavelet components of the stimulus set of data; computing separately from the computations for the stimulus set of data mean amplitude and phase variances for each of the one of spectral and wavelet components of the noise set of data; and computing for each of the one of spectral and wavelet components an F ratio of phase variance in the stimulus set of data to phase variance in the noise set of data.
- 11. The method according to claim 10, further comprising the steps of:
identifying significant components of the one of spectral and wavelet components for which the F ratio exceeds a predetermined threshold; setting to zero components not identified as significant; and performing one of an IFFT and a wavelet sum on the significant components.
- 12. The method according to claim 11, further comprising the step of computing, after the digital filtering and IFFT have been performed, mean amplitudes and variances of amplitude at each sampling point across the set of light averages.
- 13. The method according to claim 11, further comprising the step of locating latencies of successive peaks of the BAER by one of a zero crossing of a first derivative of the data, minimum valves of a second derivative of the data and directly from the FFT.
- 14. The method according to claim 12, further comprising the step of smoothing the data to reduce the number of peaks to a group of major peaks each separated by a predetermined minimum amount of time corresponding to an expected transmission delay between brainstem nuclei.
- 15. The method according to claim 13, wherein the minimum amount of time is no less than a critical value.
- 16. The method according to claim 15, wherein the critical value is approximately 0.70 milliseconds.
- 17. The method according to claim 13, further comprising the steps of:
computing a coefficient of variation (CV) as a ratio of variance to mean amplitude at each sampling point for each of the trials; and locating successive BAER peaks by one of identifying points at which values of CV are below a predetermined value and identifying points at which a first derivative of a plot of CV is zero.
- 18. The method according to claim 17, wherein the entire method is performed twice and repeated data from the repeated performance is compared to original data to determine validity of the results.
- 19. The method according to claim 12, further comprising the step of comparing the BAER data to control data obtained from one of a control group of fetuses and self-norm data collected from the same fetus during a reference period during an earlier stage of development.
- 20. The method according to claim 17, wherein threshold values of CV from control or Self-norm reference BAER data are stored in a memory and are compared to the computed CV values to determine validity of the current data.
- 21. The method according to claim 20, wherein the current BAER data are combined with previous measurements of the same subject to generate a self-norm.
- 22. The method according to claim 18, wherein peak locations from the updated and self-norm data are compared and wherein at least a plurality of peaks must be within a predetermined latency margin of one another, to estimate whether progressive changes are taking place.
- 23. A Fetal Brain Monitor for monitoring a brain wave response of a fetus in utero, comprising:
an auditory transducer producing pulsed audible sounds and adapted to be placed on an abdomen of a mother of the fetus; at least one biosensor electrode adapted to be placed on the mother's abdomen for detecting electrical activity of a brain of the fetus; a pulsing arrangement pulsing the transducer with one of rectangular waves or tone pips of a selected frequency so that it emits pulsed audible sounds at predetermined times; an amplifier connected to the at least one biosensor electrode to amplify brain stem auditory responses (BAER) of the fetus detected by the at least one biosensor electrode which are time-locked to the sounds; an analog/digital converter converting the analog BAER data to BAER digital data; and a computer-based QEEG (Quantitative EEG) system improving a signal to noise ratio of the BAER digital data and analyzing the BAER digital data.
- 24. The monitor as in claim 23, wherein the QEEG includes a digital comb filter having a plurality of band pass frequency ranges within an overall frequency range of 50-2000 Hz.
- 25. The monitor as in claim 24, wherein the QEEG collects a stimulus set of data during a stimulation period in which auditory stimuli are presented to the fetus and a noise set of data during a non-stimulation period in which no auditory stimuli are presented to the fetus, where each of the stimulus and noise sets of data are generated over a plurality of trials.
- 26. The monitor as in claim 25, wherein each of the trials comprises a plurality of EEG segments approximately 10 milliseconds in length sampled at least every 50 microseconds.
- 27. The monitor as in claim 25, wherein the QEEG constructs both the stimulus and noise sets of data in the time domain and subjects the trials to one of spectral and wavelet analysis.
- 28. The monitor as in claim 25, wherein the QEEG includes a fast fourier transform software module (“FFT module”) for subjecting the trials to one of spectral analysis and wavelet analysis.
- 29. The monitor as in claim 28, wherein the QEEG determines an amplitude and phase for one of spectral and wavelet components for each of the trials and computes mean amplitude and phase variances for each of the one of spectral and wavelet components for the stimulus set of data and wherein the QEEG computes separately from the computations for the stimulus set of data, mean amplitude and phase variances for each of the one of spectral and wavelet components of the noise set of data and computes for each of the one of spectral and wavelet components an F ratio of phase variance in the stimulus set of data to phase variance in the noise set of data.
- 30. The monitor as in claim 29, wherein the QEEG identifies significant components for which the F ratio exceeds a critical value, sets to zero components not identified as significant and performs one of an inverse wavelet and a fast fourier transfer IFFT on the significant components.
- 31. The monitor as in claim 23, further comprising a display displaying results of the QEEG analysis as an indication of a status of the BAER.
PRIORITY CLAIM
[0001] This application claims the benefit of U.S. patent application Ser. No. 09/716,517 Nov. 20, 2000 entitled “Fetal Brain Monitor” (“the '517 application”). The entire disclosure of the '517 application is expressly incorporated herein by reference.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09716517 |
Nov 2000 |
US |
Child |
10377967 |
Feb 2003 |
US |